John W. Bristol & Co’s Sanofi SNY Stock Holding History

John W. Bristol & Co’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,868	Closed	-$210K	–	84
2023 Q1	$210K	Buy	+3,868	New	+$188K	﹤0.01%	84
2021 Q3	–	Sell	-3,868	Closed	-$204K	–	93
2021 Q2	$204K	Sell	3,868 -3,132	-45%	-$163K	﹤0.01%	90
2021 Q1	$346K	Hold	7,000	–	–	0.01%	80
2020 Q4	$340K	Hold	7,000	–	–	0.01%	72
2020 Q3	$351K	Buy	+7,000	New	+$360K	0.01%	69

Other funds holding SNY

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

John W. Bristol & Co's SNY Position: Q2 2023 in Review

John W. Bristol & Co sold out of Sanofi (SNY) in Q2 2023, closing a stake of 3,868 shares — an estimated $210K sold.

John W. Bristol & Co first reported a position in SNY in Q3 2020 and held it in 5 quarters. The position peaked at $351K in Q3 2020. 672 funds tracked by Wall St. Rank hold SNY as of Q2 2023.

John W. Bristol & Co reported no remaining Sanofi position as of Q2 2023 after selling out during the quarter.
John W. Bristol & Co sold 3,868 Sanofi shares in Q2 2023, an estimated $210K.
John W. Bristol & Co first reported a position in Sanofi in Q3 2020 and held it in 5 quarters.
John W. Bristol & Co's Sanofi position peaked at $351K in Q3 2020.
672 funds tracked by Wall St. Rank held Sanofi as of Q2 2023.

Based on John W. Bristol & Co's 13F filing for Q2 2023, filed 28 Jul 2023.